BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 25585275)

  • 1. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
    MacMillan ML; Robin M; Harris AC; DeFor TE; Martin PJ; Alousi A; Ho VT; Bolaños-Meade J; Ferrara JL; Jones R; Arora M; Blazar BR; Holtan SG; Jacobsohn D; Pasquini M; Socie G; Antin JH; Levine JE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):761-7. PubMed ID: 25585275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score.
    MacMillan ML; DeFor TE; Weisdorf DJ
    Br J Haematol; 2012 Jun; 157(6):732-41. PubMed ID: 22486355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.
    El-Jawahri A; Li S; Antin JH; Spitzer TR; Armand PA; Koreth J; Nikiforow S; Ballen KK; Ho VT; Alyea EP; Dey BR; McAfee SL; Glotzbecker BE; Soiffer RJ; Cutler CS; Chen YB
    Biol Blood Marrow Transplant; 2016 May; 22(5):910-8. PubMed ID: 26748160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score.
    Kharfan-Dabaja MA; Sheets K; Kumar A; Murthy HS; Nishihori T; Tsalatsanis A; Mina A; Mathews J; Ayala E; Chavez J; Perez LE; Betts BC; Anasetti C; Pidala J
    Br J Haematol; 2018 Mar; 180(6):854-862. PubMed ID: 29345306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease.
    García-Cadenas I; Rivera I; Martino R; Esquirol A; Barba P; Novelli S; Orti G; Briones J; Brunet S; Valcarcel D; Sierra J
    Bone Marrow Transplant; 2017 Jan; 52(1):107-113. PubMed ID: 27595281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
    MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients.
    Campregher PV; Hamerschlak N; Colturato VA; Mauad MA; de Souza MP; Bouzas LF; Tavares Rde C; Barros JC; Chiattone R; Paz A; Silla L; Vigorito AC; Miranda E; Funke VA; Flowers ME
    Eur J Haematol; 2015 Nov; 95(5):421-5. PubMed ID: 25645430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
    Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
    Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.
    Vaughn JE; Gooley T; Maziarz RT; Pulsipher MA; Bhatia S; Maloney DG; Sandmaier BM; Flowers ME; Storb R; Sorror ML
    Br J Haematol; 2015 Nov; 171(3):411-6. PubMed ID: 26194447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia.
    Kato M; Kurata M; Kanda J; Kato K; Tomizawa D; Kudo K; Yoshida N; Watanabe K; Shimada H; Inagaki J; Koh K; Goto H; Kato K; Cho Y; Yuza Y; Ogawa A; Okada K; Inoue M; Hashii Y; Teshima T; Murata M; Atsuta Y
    Bone Marrow Transplant; 2019 Jan; 54(1):68-75. PubMed ID: 29795428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.
    Sung AD; Hassan S; Cardona DM; Wild D; Nichols KR; Mehdikhani H; Balmadrid B; Detweiler CJ; Shealy M; Cirrincione C; Li Z; Poleski M; Dalton TE; Siamakpour-Reihani S; Chao NJ; Sullivan KM
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):734-740. PubMed ID: 29246821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease.
    Inamoto Y; Flowers ME; Sandmaier BM; Aki SZ; Carpenter PA; Lee SJ; Storer BE; Martin PJ
    Blood; 2014 Aug; 124(8):1363-71. PubMed ID: 24876566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
    Kennedy GA; Varelias A; Vuckovic S; Le Texier L; Gartlan KH; Zhang P; Thomas G; Anderson L; Boyle G; Cloonan N; Leach J; Sturgeon E; Avery J; Olver SD; Lor M; Misra AK; Hutchins C; Morton AJ; Durrant ST; Subramoniapillai E; Butler JP; Curley CI; MacDonald KPA; Tey SK; Hill GR
    Lancet Oncol; 2014 Dec; 15(13):1451-1459. PubMed ID: 25456364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
    Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
    Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 genotype of the donor is associated with acute graft-versus-host disease after HLA-identical sibling donor stem cell transplantation.
    Santos N; Rodríguez-Romanos R; de la Cámara R; Brunet S; Nieto JB; Buño I; Martínez C; Jiménez-Velasco A; Vallejo C; González M; Solano C; Ferrá C; Sampol A; Pérez-Simón JA; López-Jiménez J; Díez JL; Gallardo D;
    Ann Hematol; 2018 Nov; 97(11):2217-2224. PubMed ID: 30019128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
    Levine JE; Braun TM; Harris AC; Holler E; Taylor A; Miller H; Magenau J; Weisdorf DJ; Ho VT; Bolaños-Meade J; Alousi AM; Ferrara JL;
    Lancet Haematol; 2015 Jan; 2(1):e21-9. PubMed ID: 26687425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Remberger M; Kumlien G; Aschan J; Barkholt L; Hentschke P; Ljungman P; Mattsson J; Svennilson J; Ringdén O
    Biol Blood Marrow Transplant; 2002; 8(12):674-82. PubMed ID: 12523580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies.
    Inagaki J; Fukano R; Noguchi M; Okamura J
    Int J Hematol; 2017 May; 105(5):676-685. PubMed ID: 28205066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.